

Mouse flt3-Ligand (flk2-Ligand) - Purified

Catalog No.:	PA1020XC
Quantity:	1 mg
Background:	FLT3 ligand is a receptor for the fl cytokine has a tyrosine-protein kinase activity & a growth factor that regulates proliferation of early hematopoietic cells. Flt3-Ligand synergizes with other CSFs and interleukins to induce growth and differentiation.
Species:	Mouse
Source:	E. coli
Format:	State: Sterile filtered, white lyophilized powder without additives Purity: >98% greater than 98.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by reducing and non-reducing SDS-PAGE Reconstitution: It is recommended to reconstitute the lyophilized Flt3-Ligand in sterile 18 MΩ-cm H ₂ O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
Description:	Flt3-Ligand Mouse Recombinant produced in E.coli is non-glycosylated, polypeptide chain containing 144 amino acids. The sequence of the first five N-terminal amino acids was determined and was found to be Thr-Gln-Asp-Cys-Ser. Flt3-Ligand is purified by proprietary chromatographic techniques. Biological Activity: The activity is determined by the ability to generate CD11c+ splenic dendritic cells in vivo in C57B1/6-12 week female mice. To obtain the desired affect, mice were treated with approximately 25ug of flt3-ligand once daily for 9 consecutive days via intraperitoneal injection. Molecular weight: 16 kDa 16431 Dalton
Storage:	Lyophilized FLT3-Ligand although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT3 should be stored at 2-8°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles. Shelf life: one year from despatch.
General Readings:	<ol style="list-style-type: none">1. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. J Immunother 2004 Jan-Feb;27(1):13-262. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother 2003 Sep;52(9):535-453. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int J Cancer 2003 Dec 10;107(5):773-80

4. Flt3 ligand: a novel cytokine prevents allergic asthma in a mouse model.

Int Immunopharmacol 2001 Nov;1(12):2081-9

5. Neutralization of IL-12 reverses rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with suppression of both cellular and humoral responses.

Transplant Proc 2001 Feb-Mar;33(1-2):525